Number of high-risk diabetic patients with antiplatelet drug prescriptions at baseline and at the end of the follow-up
| Control | Intervention | OR (95% CI) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| High-risk diabetic subjects (n) | Antiplatelet users | High-risk diabetic subjects (n) | Antiplatelet users | ||||||||||||
| Type of risk* | Baseline (%) | Follow-up (%) | Effect size (%) | Baseline (%) | Follow-up (%) | Effect size (%) | |||||||||
| Group 1 | 2,578 | 263 (10.2) | 440 (17.1) | 177 (6.9) | 2,651 | 358 (13.5) | 736 (27.8) | 378 (14.3) | 2.38 (1.97–2.87) | ||||||
| Group 2 | 1,440 | 180 (12.5) | 276 (19.2) | 9.6 (6.7) | 1,577 | 224 (14.2) | 508 (32.2) | 284 (18.0) | 3.22 (2.52–4.12) | ||||||
| Group 3 | 3,295 | 1,229 (37.3) | 1,526 (46.3) | 297 (9.0) | 3,802 | 1,304 (34.3) | 1,768 (46.5) | 464 (12.2) | 1.36 (1.16–1.59) | ||||||
| Total | 7,313 | 1,672 (22.9) | 2,242 (30.7) | 570 (7.8)† | 8,030 | 1,886 (23.5) | 3,012 (37.5) | 1,126 (14.0)† | 1.99 (1.79–2.22) | ||||||